Join
Live feed
·
PRReleasevia Quantisnow
PTC Therapeutics Inc. logo

PTC Therapeutics to Host Call to Review Results from its Study of Translarna™ (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy

ByQuantisnow·Wall Street's wire, on your screen.
PTCT· PTC Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PTCT (PTC Therapeutics Inc.) and more on Quantisnow.